Clinical Scorecard: Evaluating the Diagnostic Efficacy of Fecal Eosinophil-Derived Neurotoxin and Lipocalin-2 in Children with Inflammatory Bowel Disease
At a Glance
Category
Detail
Condition
Inflammatory Bowel Disease (IBD)
Key Mechanisms
Involves chronic inflammation of the gastrointestinal tract, with biomarkers like fecal eosinophil-derived neurotoxin (fEDN) and lipocalin-2 (LCN-2) being evaluated for diagnostic efficacy.
Target Population
Children and adolescents diagnosed with IBD.
Care Setting
Pediatric Gastroenterology Unit and GIT Endoscopy Unit
Key Highlights
IBD includes ulcerative colitis and Crohn’s disease, with rising incidence in pediatric populations.
Fecal biomarkers fEDN and LCN-2 are being studied for their potential role in non-invasive diagnosis.
Endoscopy remains the gold standard for IBD diagnosis, complemented by histological evaluation.
Guideline-Based Recommendations
Diagnosis
Diagnosis of IBD requires clinical presentation, endoscopic evaluation, and histological assessment.
Management
Endoscopic and histological evaluations are essential for defining disease severity.
Monitoring & Follow-up
Monitoring of fecal biomarkers may support assessment of intestinal inflammation.
Risks
Potential limitations of fecal biomarkers include day-to-day variations and lack of specificity for IBD.
Patient & Prescribing Data
Children under 18 years diagnosed with inflammatory bowel disease.
Inclusion criteria focus on patients accepting participation and excluding those with critical health issues.
Clinical Best Practices
Utilize a combination of clinical, laboratory, and endoscopic evaluations for accurate diagnosis.
Consider the role of fecal biomarkers as complementary tools in assessing IBD.
